Price T Rowe Associates Inc Verona Pharma PLC Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Verona Pharma PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,335,194 shares of VRNA stock, worth $64.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,335,194
Previous 949,375
40.64%
Holding current value
$64.4 Million
Previous $13.7 Million
179.82%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VRNA
# of Institutions
167Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$304 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$269 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$241 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$203 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$171 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $2.94B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...